

DAFTAR PUSTAKA

- Adieba, W. (2021). *Penggunaan Klorokuin Pada Infeksi Virus Covid-19*. Jawa Tengah : Institut Agama Islam Negri Kudus.
- Andi, P. (2021). *Analisis Efektivitas Biaya Penggunaan Antibiotik Levofloksasin dan Azitromisin Pada Pasien Penderita Corona Virus Disease-2019*. Makassar : Universitas Muslim Indonesia.
- ASHP. (2020). *Assesment of evidence for COVID - 19 releated treatmens*, update 5/21/2020.
- Bacharier. (2015). *Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial*, JAMA 2015;314:2034–44.
- Bacharier, L et al. (2015). *Early Administration Of Azithromycin and Prevention Of Severe Lower Respiratory Tract Illnesses*. JAMA-J. Am. Med. Assoc. 314, 2034–2044.
- Bahtera, D. P. (2020). *Gambaran Tatalaksana Terapi Pada Pasien Covid-19 Terkonfirmasi Di Rumah Sakit X Kota Surakarta Periode Maret - Desember 2020*, Surakarta : Sekolah Tinggi Ilmu Kesehatan Nasional.
- Barker, H. (2020). *Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2.*, bioRxiv.
- Bradley, J. (2020). *Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis*. . Clinical Microbiology and Infection, 26(12), 1622–1629.
- Cai Q. (2020). *Experimental Treatment With Favipiravir for COVID-19: An Open-Label Control Study*. Eng Beijing China. Oct;6(10):1192–8.
- Casella, M. (2020). *Features, evaluation and treatment coronavirus (COVID-19).*, Stat pearls [internet]. Treasure Island (FL): Stat Pearls Publishing.
- CDC. (2020). *Coronavirus Disease 2019 (COVID-19)*, Diakses dari <https://www.cdc.gov/coronavirus/2019-ncox/index.html>, pada tanggal 29 November 2021.

- Dehelean, C. A. (2020). *SARS-CoV-2 : Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.* , Journal of Clinical Medicine. 9(7), p. 1-40.
- Dharma. (2011). *Metodologi Penelitian keperawatan*, Jakarta :CV. Trans Info Media.
- Dinkes, K. S. (2021). Retrieved from <http://corona.samarindakota.go.id>
- Donsu, Y. (2020). *Tinjauan azitromisin pada penyakit virus korona 2019 (Covid-19)*, Pharmacon: J Farm Indones. 17 (2). p133-47.
- Du, et al. (2020). *Risk for transportation*, Emerg. Infect. Dis., doi: 10.3201/eid2605.200146.
- Eljaaly, K. (2017). Clinical Failure With and Without Empiric Atypical Bacteria Coverage In Hospitalized Adults. BMC Infect. Dis. 17, 1–7.
- Erna, P. (2020). Penggunaan Antibiotik Pada Pasien Covid-19 Di Rumah Sakit 'X" KOTA SEMARANG.
- Fernandez-Atucha, A. (2017). *Sex differences in the aging pattern of renin-angiotensin system serum peptidases.* , Biol Sex Differ ;8:5:1-8.
- Gemmati, D. B. (2020). COVID-19 and Individual Genetic Susceptibility/Receptivity : Role of ACEI/ACE2 Genes, Immunity, Inflammation, and Coagulation. Might the Double X-Chromosome in Females be Protective Against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. Int. J. Mol Sci; 2020. 10 : 3474.
- Guan, et al (2019). *Clinical Characteristics of Coronavirus Disease 2019 in China.*, The New England journal of medicine. published February 2020. DOI: 10.1056/NEJMoa2002032. Available on: <https://www.nejm.org/doi/full/10.1056/NEJMoa2002032>.
- Habibzadeh, & Stoneman, E. (2020). *The Novel Coronavirus: A Bird's Eye View*, The International Journal of Occupational and Environmental Medicine. 11 (2): 65–71.
- Izzedine, H. (2020). COVID19 Therapeutic Options for Patients with Kidney Disease', Kidney International. doi: 10.1016/j.kint.2020.03.015.

- Katzung, B. (2016). *Basic and clinical pharmacology, Tenth Edition.*, Lange Medical Publications, United State.p851-99.
- Kemenkes. (2011). *Modul Penggunaan Obat Rasional*, Bina Pelayanan Kefarmasian, Jakarta.
- Kordzadeh-Kermani. (2020). *Pathogenesis, clinical manifestations and complications of COVID-19.*, Future Microbiology, 15(13), 1287–.
- Lagocka, R. (2021). Favipiravir in therapy of viral infections. J Clin Med. Feb;103:62–71. .
- Lapostolle, F. (2020). *Clinical Features of 1487 COVID - 19 Patients with Outpatient Management in the Greater Paris : the COVID - Call Study.*, Internal and Emergency Medicine, (0123456789). <https://doi.org/10.1007/s11739-020-02379-z>.
- Lavan. (2016). Predicting Risk of Adverse drug Reactions in Older Adults. Ther Adv Drug Saf; 2016. 7(1):11-22.
- Li M. (2021). Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: A randomized. Braz J Med Biol Res. 2021;54(2):e9542.
- Lina, M. (2021). Analisis perbandingan Lama Rawat Inap Pasien Terdiagnosis Covid-19 Antara Pemberian Terapi Oseltamivir Dengan Favipiravir di RSUD R. Syamsudin S.H Sukabumi. Bandung : Politeknik Piksi Ganesha.
- Lisni, I et al. (2021). *Antibiotic Profile For Covid-19 Treatment*, Bandung : Universitas Bhakti Kencana.
- Liu, Q. (2014). Emergence of a Novel Drug Resistant H7N9 Influenza Virus: Evidence Based Clinical Potential of a Natural IFN- α for Infection Control and Treatment. Expert Review of Anti Infective Therapy, 12(2), 165-169.
- Masturoh, I. (2018). *Metodologi Penelitian Kesehatan*, Jakarta : Kebayoran Baru.
- Metlay, J. (2020). Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. . Annals of Internal Medicine, 1-3, doi: 10.7326/M20-2189.

- Nasution, N. H. (2021). Gambaran pengetahuan Masyarakat Tentang Pencegahan Covid-19 di kecamatan Padangsidimpuan Batunadua, kota Padangsidimpuan. *Jurnal Kesehatan Ilmiah Indonesia*, Vol 6.
- PAPDI. (2020). *Pedoman Tatalaksana Covid-19 Edisi 3.*, Jakarta.
- Paramita, S. E. (2020). *Epidemiological Characteristics of COVID-19 Patients in Samarinda*, East Kalimantan, Indonesia.
- PDPI. (2020). *Pedoman Tatalaksana COVID-19 Pedoman Tatalaksana COVID-19 Edisi 3 Desember 2020.*
- Pharmaceutical, T. (2020). *China Approces First Anti-viral Drug Againts Coronavirus COVD - 19*, Last Update : 2020 February 18.
- PPID et al. (2021). *Tren Kasus Covid-19 Menurun, Pemkot Samarinda Pertimbangkan Beri Kelonggaran Secara Bertahap*. Retrieved from <https://ppid.samarindakota.go.id/berita/kesehatan/tren-kasus-covid-19-menurun-pemkot-samarinda-pertimbangkan-beri-kelonggaran-secara-bertahap>
- Prabowo, R. (2013). *Jurnal Ilmiah Cendekia Eksakta 55*, Jurnal Ilmiah Cendekia Eksakta 2(82): 55-61.
- Pratiwi, R. (2017). Mekanisme Pertahanan Bakteri Patogen Terhadap Antibiotik. *Pro Life*, 4 (3): 418-429.
- Rossignol, J. (2014). *Nitazoxanide: a first-in-class broad-spectrum antiviral agent*, 110: 94–103.
- Sartika, E. (2021). *Edukasi Vitamin yang Tepat Masa Pandemi Covid-19*, Medan : Sekolah Tinggi Ilmu Kesehatan Indah Medan.
- Setiadi, A. A. (2020). *Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif*, Jurnal Farmasi Klinik Indonesia, 9 (1): 70-94.
- Sieswerda, E. (2020). Recommendations For Antibacterial Therapy In Adults With COVID19—an Evidence Based Guideline, *Clinical Microbiology and Infection*. , 27 (1): 61-66.
- Sifriyani, A. D. (2020). *Pemodelan Susceptible Infected Recovered (Sir) Untuk Estimasi Angka Reproduksi Covid - 19 Di Kalimantan Timur Dan Samarinda*, Jurnal Media Statistika (July). 1 - 13.
- Simon, A. (2015). Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci [Internet]* 2015;282(1821):20143085.

Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707740/>.

- Styawan, D. A. (2020). *Pandemi Covid-19 dalam Perspektif Demografi*, Seminar Nasional Official Statistics, 2020(1), 182–189. <https://doi.org/10.34123/>.
- Susilo, A et al. (2020). *Coronavirus disease 2019 tinjauan literatur terkini.*, J Penyakit Dalam [serial online]. 2020; 7(1). p45-67. DOI: 10.7454/jpdi.v7i1.415.
- Wang, Y. (2020). Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir. *J Infect Dis.* 2020 Apr 27;221(10):1688–98.
- Whalen, K. (2019). *Lippincott illustrated reviews: pharmacology 7 th ed. Philadelphia.*
- WHO. (2020a). *Coronavirus Disease 2019 (COVID-19) Pandemic*, Diakses dari <https://www.who.int/emergencies/disease/novel-coronavirus-2019>, pada tanggal 29 November 2021.
- WHO. (2020b). *Coronavirus Disease 2019 (COVID-19) Pandemic*, Diakses dari <https://www.who.int/emergencies/disease/novel-coronavirus-2019>, pada tanggal 29 November 2021.
- WHO. (2020c). *Coronavirus Disease 2019 (COVID-19) Pandemic.*, Diakses dari <https://www.who.int/emergencies/disease/novel-coronavirus-2019>, pada tanggal 29 November 2021. Retrieved from <https://covid19.who.int/>
- Widayati, L. P., & Mustika, I. (2021). *Sikap Remaja Terhadap Upaya Pencegahan Penyebaran Covid-19 Pada Orang Tanpa Gejala (OTG) di Surabaya*, *Jl-KES (Jurnal Ilmu Kesehatan)*, 4(2), 36-44.
- Wirda, A. E. (2020). Pengaruh Pemberian edukasi Terhadap Tingkat Pengetahuan Pasien Rawat Jalan tentang Penggunaan Antibiotik Di RSUD Kanjuruhan Kabupaten Malang. *Pharmaceutical Journal Of Indonesia*, 6(1);57-62.
- Yao, T et al. (2020). *A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option.*, *J Med Virol* 2020;92:556–63.

Zhou, F et al. (2020). *Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.*, Lancet; published online March 2020. DOI: 10.1016/S0140-6736(20)30566-3.